Industrial Services Of America Inc (NASDAQ:IDSA): Negative Stock Sentiment

Sentiment for Industrial Services Of America Inc (NASDAQ:IDSA)

Industrial Services Of America Inc (NASDAQ:IDSA) institutional sentiment decreased to 0.75 in Q2 2019. Its down -0.58, from 1.33 in 2019Q1. The ratio has worsened, as 3 institutional investors started new or increased stock positions, while 4 trimmed and sold holdings in Industrial Services Of America Inc. The institutional investors in our partner’s database now have: 241,285 shares, down from 247,950 shares in 2019Q1. Also, the number of institutional investors holding Industrial Services Of America Inc in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 2 Reduced: 2 Increased: 2 New Position: 1.

Industrial Services of America, Inc

It closed at $1.14 lastly. It is down 49.84% since September 13, 2018 and is downtrending. It has underperformed by 49.84% the S&P500.

Stock Yards Bank & Trust Co holds 0.01% of its portfolio in Industrial Services of America, Inc. for 78,000 shares. Blackrock Inc. owns 6,500 shares or 0% of their US portfolio. Moreover, Citadel Advisors Llc has 0% invested in the company for 26,098 shares. The Texas-based Dimensional Fund Advisors Lp has invested 0% in the stock. Geode Capital Management Llc, a Massachusetts-based fund reported 15,157 shares.

More notable recent Industrial Services of America, Inc. (NASDAQ:IDSA) news were published by: which released: “Industrial Services of America, Inc. Announces Fourth Quarter 2018 Financial Results – Business Wire” on March 13, 2019, also with their article: “Louisville company could be delisted from Nasdaq – Louisville Business First” published on August 15, 2019, published: “Vanguard FTSE Emerging Markets ETF Experiences Big Outflow – Nasdaq” on March 27, 2018. More interesting news about Industrial Services of America, Inc. (NASDAQ:IDSA) were released by: and their article: “Citius Pharmaceuticals Presents Data on Mino-Lok® Showing 98% Clinical Efficacy – Yahoo Finance” published on April 30, 2019 as well as‘s news article titled: “Nabriva Therapeutics to Present Data at ID Week Demonstrating Potential of Lefamulin for Patients with Community-acquired Bacterial Pneumonia (CABP) and CONTEPOâ„¢ (fosfomycin for injection) to Treat Complicated Urinary Tract Infections (cUTIs) – GlobeNewswire” with publication date: September 28, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.